AL Amyloidosis clinical trials at University of California Health
9 in progress, 4 open to eligible people
JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
open to eligible people ages 18 years and up
The primary purpose of this study is to identify the recommended phase 2 dose (RP2D[s]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s) selected…
at UCSF
Birtamimab in Mayo Stage IV Patients with AL Amyloidosis
open to eligible people ages 18 years and up
A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in Mayo Stage IV patients with AL amyloidosis.
at UCSF
NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
open to eligible people ages 18-120
Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).
at UC Davis UCLA
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
open to eligible people ages 18 years and up
This phase I/Ia trial finds the best dose and side effects of venetoclax given in combination with ixazomib citrate and dexamethasone in treating patients with light chain amyloidosis that has come back (relapsed) or does not respond to treatment…
at UC Davis
CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
Sorry, in progress, not accepting new patients
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space …
at UCSF
CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
Sorry, in progress, not accepting new patients
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space …
at UCSF
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Sorry, in progress, not accepting new patients
This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment. Monoclonal antibodies, such as isatuximab, may interfere with the ability of cancer cells to…
at UC Davis UC Irvine
Cardiac Amyloidosis Registry Study
Sorry, accepting new patients by invitation only
This registry is a observational, multi-center study designed to collect data and analyze it retrospectively on patients with cardiac amyloidosis who have been evaluated and treated at major amyloid centers across the US and internationally between…
at UC Davis UCSD UCSF
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Sorry, not currently recruiting here
In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is observation not treatment. The main goal of this…
at UC Irvine UCSF
Our lead scientists for AL Amyloidosis research studies include Gary J. Schiller, MD Darren Pan Aaron Rosenberg Alfred Chung.
Last updated: